Runben Biotechnology (SH:603193)2023-10-26 16:00Financial Performance - The company's operating revenue for Q3 2023 was CNY 244,376,848.52, representing a year-on-year increase of 0.91%[5] - The net profit attributable to shareholders for Q3 2023 was CNY 61,265,308.93, reflecting a year-on-year growth of 15.75%[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 58,584,235.07, with a year-to-date increase of 12.92%[5] - The company's gross profit margin improved by 2.06%, with gross profit increasing by 25.52% year-on-year[10] - The company reported a year-to-date increase in net profit of 37.47% compared to the same period last year[10] - Operating profit for Q3 2023 was ¥216,401,777.10, up 37.4% from ¥157,428,955.63 in Q3 2022[22] - Net profit for the first three quarters of 2023 was ¥180,733,960.84, representing a 37.5% increase compared to ¥131,476,199.09 in the same period last year[23] Earnings Per Share - The basic earnings per share for Q3 2023 was CNY 0.18, up 15.75% from the same period last year[6] - The diluted earnings per share also stood at CNY 0.18, reflecting the same growth rate of 15.75%[6] - Basic and diluted earnings per share for Q3 2023 were both ¥0.53, compared to ¥0.38 in Q3 2022, reflecting a 39.5% increase[23] Assets and Liabilities - The total assets at the end of the reporting period amounted to CNY 986,687,828.84, marking a 19.54% increase compared to the end of the previous year[6] - The company's current assets reached CNY 677,882,451.37, up from CNY 510,043,863.09 in the previous year, indicating a year-over-year increase of about 32.9%[16] - Cash and cash equivalents stood at CNY 458,595,188.40, compared to CNY 368,213,351.52 at the end of 2022, reflecting a growth of approximately 24.5%[16] - The total liabilities decreased to CNY 81,793,206.90 from CNY 102,833,345.20, showing a reduction of about 20.5%[18] - The total current liabilities were reported at CNY 78,813,012.35, down from CNY 96,598,979.36, reflecting a decrease of approximately 18.4%[18] Equity - The equity attributable to shareholders reached CNY 904,894,621.94, which is a 25.23% increase year-on-year[6] - The company's equity attributable to shareholders increased to CNY 904,894,621.94, up from CNY 722,586,852.17, marking a growth of approximately 25.2%[18] - The total equity increased by CNY 182,307,769.77, representing a growth of approximately 25.2% year-over-year[18] Cash Flow - The cash flow generated from operating activities for the year-to-date period was CNY 190,109,983.91, showing an increase of 36.54%[6] - Cash flow from operating activities for the first three quarters of 2023 was ¥190,109,983.91, an increase from ¥139,236,769.35 in the same period of 2022[25] - The company received cash inflows from operating activities totaling ¥932,218,237.00 in the first three quarters of 2023, compared to ¥773,637,265.68 in the same period of 2022, marking a 20.5% increase[24] Research and Development - Research and development expenses for the first three quarters of 2023 were ¥18,255,343.87, an increase of 29% from ¥14,137,496.60 in the same period of 2022[21] Operating Costs - Total operating costs for the first three quarters of 2023 were ¥611,989,929.02, a 16.5% increase from ¥525,181,651.79 in the same period of 2022[21] Investment Activities - The company reported a net cash outflow from investing activities of ¥95,787,407.44 for the first three quarters of 2023, compared to a net outflow of ¥78,649,621.32 in the same period of 2022[25]